VivoSeq
Other

Buprenorphine

0

Pipeline Programs↗

18

Active Trials↗

11

Companies Involved↗

Buprenorphine is an early-stage landscape with 0 programs across 11 companies. The most active players are Purdue Pharma LP, INSYS Therapeutics Inc, Vertex Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

25/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Purdue Pharma LP

0 programs

PreclinicalI

INSYS Therapeutics Inc

0 programs

PreclinicalVertex Pharmaceuticals logo

Vertex Pharmaceuticals

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

189

clinical trials

Completed135 · 71%
Unknown status14 · 7%
Terminated12 · 6%
Withdrawn9 · 5%
Recruiting8 · 4%
Not yet recruiting7 · 4%
Other4 · 2%

Clinical Trials

Trial Activity

189 trials

Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl
Recruiting·JJohns Hopkins University·Phase 3·NCT06089707·25 enrolled
Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans
Recruiting·PPharmacotherapies for Alcohol and Substance Use Disorders Alliance·Phase 2·NCT04360681·120 enrolled
Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
Recruiting·JJohns Hopkins University·Phase 2·NCT05145764·120 enrolled
Buprenorphine for Individuals in Jail
Recruiting·FFriends Research Institute, Inc.·Phase 3·NCT06306443·240 enrolled
High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)
Recruiting·RRutgers, The State University of New Jersey·Phase 3·NCT05589181·140 enrolled
Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments
Recruiting·UUniversity of British Columbia·Phase 2/3·NCT04893525·658 enrolled
Kratom Use Disorder Management Using Clonidine and/or Buprenorphine
Recruiting·SSalem Anaesthesia Pain Clinic·N/A·NCT05883358·50 enrolled
Standard Versus High Dose ED-Initiated Buprenorphine Induction
Recruiting·YYale University·Phase 3·NCT06494904·360 enrolled
Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail
Active, not recruiting·FFriends Research Institute, Inc.·Phase 2/3·NCT04408313·240 enrolled
Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
Active, not recruiting·—·Phase 3·NCT06023459·144 enrolled
Low-dose Versus a High-dose Sublingual Buprenorphine Induction
Active, not recruiting·FFriends Research Institute, Inc.·Phase 4·NCT05944952·40 enrolled
Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual
Not yet recruiting·NNew York State Psychiatric Institute·Phase 2·NCT05339256·50 enrolled
Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic
Not yet recruiting·YYale University·Phase 4·NCT07176351·60 enrolled
Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation
Not yet recruiting·UUniversity of California, San Francisco·Phase 4·NCT07469501·50 enrolled
Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
Not yet recruiting·MMontefiore Medical Center·Phase 3·NCT07148206·40 enrolled
Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)